In general the program’s research will address a broader range of medical needs including in vivo imaging of disease states, in vitro diagnosis, in vivo drug/gene delivery, and stem cell technologies for tissue repair, with an emphasis on translating the innovative nanotechnologies to clinical utility.

The program’s research aim to further develop the nano-scale tools and nano-cardiology knowledge base, to translate the new tools and nanotechnologies to clinical applications in diagnosing and treating cardiovascular disease, and to train the next generation of leaders in cardiovascular nanomedicine, and therefore includes projects in the following specific areas:

  • Synthesis, functionalization and evaluation of nanoparticle probes for in vivo MR and PET imaging and characterization of nanoparticle-vessel interactions
  • Development and validation of nanoprobe-based assays for in vitro diagnostics with improved sensitivity
  • Development of in vivo drug/gene delivery strategies for new therapeutics
  • Nanotechnology based approaches for producing patient-specific endothelial cells and cardiomyocytes for repairing damaged tissue

External funding:  The program was awarded $14.6 million from the National Heart, Lung, and Blood Institute (NHLBI), one of National Institutes of Health (NIH) in 2010.


1. Hamzah J, Kotamraju VR. Seo JW, Agemy LFV, Mahakian LM, Peters D, Roth L, Gagnon MKJ, Ferrara KW and Ruoslahti E. “Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of ApoE deficient mice”. PNAS, 2011 Apr 26;108(17):7154-9. Epub 2011 Apr 11. PMCID: PMC3084060.

2. Jin-Ok Jeong, Ji Woong Han, Jin-Man Kim, Hyun-Jai Cho, Changwon Park, Namho Lee, Dong-Wook Kim, Young-Sup Yoon. “Malignant Tumor Formation After Transplantation of Short-Term Cultured Bone Marrow Mesenchymal Stem Cells in Experimental Myocardial Infarction and Diabetic Neuropathy”, Circulation Research, April 14, 2011. PMCID: PMC3109741.

3. Sung-Whan Kim, Hyongbum Kim, and Young-sup Yoon. “Advances in bone marrow-derived cell therapy: CD31-expressing cells as next generation cardiovascular cell therapy.” Regenerative Medicine (2011) 6(3), 335-349. PMCID: 3129287.

4. Sheng Tong, Sijian Hou, Zhilan Zheng, Jun Zhou, and Gang Bao. “Coating Optimization of Superparamagnetic Iron Oxide Nanoparticles for High T2 Relaxivity.” Nano Letters. 2010 Nov 10;10(11):4607-13. PMCID: 3170660. 

5. Han JW and Yoon YS. “Induced Pluripotent Stem Cells: Emerging Techniques for Nuclear Reprogramming”. Antioxidant and Redox Signaling, Jan 2011. PMCID: 3159104.